Received Mar 19, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 4 | Unknown | PO / MO |
The patient took the fourth dose of Vivotif a day early; Case reference number US-BN-2025-001573 is a spontaneous case initially received from a consumer via Med Communications (reference number: USBAV25-2319) on 18-Sep-2025 and concerns a female patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On an unspecified date, the patient took the first dose of Vivotif (batch number: unknown) at an unknown dose, orally, for an unknown indication. On an unspecified date, 48 h after the first dose, the patient took the second dose of Vivotif (batch number: unknown) at an unknown dose, orally. On an unspecified date, 48 h after the second dose, the patient took the third dose of Vivotif (batch number: unknown) at an unknown dose, orally. On an unspecified date, 24 h after the third dose, the patient took the fourth dose of Vivotif (batch number: unknown) at an unknown dose, orally (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif. No additional information was provided.; Reporter's Comments: A female patient of unspecified age took the fourth dose of Vivotif for an unknown indication 24h after the third dose, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif. Inappropriate schedule of vaccine administered is considered as listed per company convention. The patient's relevant medical history and concomitant medication details were not provided. Inappropriate schedule of vaccine administered is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A female patient of unspecified age took the fourth dose of Vivotif for an unknown indication 24h after the third dose, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif. Inappropriate schedule of vaccine administered is considered as listed per company convention. The patient's relevant medical history and concomitant medication details were not provided. Inappropriate schedule of vaccine administered is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: NONE